Konski Quoted on Patent Office's Post-Myriad Guide

13 March 2014 FDA Week News

FDA Week

Partner Antoinette Konski was quoted in an FDA Week article on March 13, 2014 titled, “Gene Patent Experts Disagree About Patent Office’s Post-Myriad Guide.” The article discusses how experts are split on new guidance from the U.S. Patent and Trademark Office outlining when products that use naturally occurring genetic materials are patentable following a Supreme Court decision invalidating patents on naturally occurring DNA. Konski was quoted saying, “The guidance does not provide clear examples of marked differences that relate to current technology.”

Related Services

Insights

A Review of Recent Whistleblower Developments
19 July 2019
Legal News: Whistleblower Developments
Cloud security inadequate for Cyber threats, are you surprised?
19 July 2019
Internet, IT & e-Discovery Blog
Blockchain: A Tool With a Future in Healthcare
18 July 2019
Health Care Law Today
Do You Know What IMMEX Stands For?
16 July 2019
Dashboard Insights
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
2019 NDI Executive Exchange
14-15 November 2019
Chicago, IL
MAGI’s Clinical Research Conference
29 October 2019
Las Vegas, NV
Association for Corporate Counsel Annual Meeting 2019
27-30 October 2019
Phoenix, AZ